Original Article

Association of p53 Expression with Metabolic Features of Stage I Non-Small Cell Lung Cancer

Shin Myung Kang, M.D.[1,2], Won-Jung Koh, M.D.[1], Gee Young Suh, M.D.[1], Man Pyo Chung, M.D.[1], Joungho Han, M.D.[3], Hojoong Kim, M.D.[1], O Jung Kwon, M.D.[1], Sang-Won Um, M.D.[1]

[1]Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, [2]Department of Pulmonary and Critical Care Medicine, Gachon University Gil Hospital, Incheon, [3]Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Background: Recent evidences have revealed metabolic functions of p53 in cancer cells; adaptation or survival to metabolic stress and metabolic shift toward oxidative phosphorylation. However, further studies in clinical setting are needed. We investigated whether p53 protein expression, as a surrogate marker for loss of p53 function, is associated with metabolic features of stage I non-small cell lung cancer (NSCLC), focusing on tumor necrosis and maximal standardized uptake value (SUVmax) on ^{18}F-fluorodeoxyglucose positron emission tomography.

Methods: Clinical information was obtained from retrospective review of medical records. p53 expression was assessed by immunohistochemical staining.

Results: p53 protein expression was detected in 112 (46%) of 241 NSCLC cases included in this study. p53 expression was independently associated with the presence of necrosis (odds ratio [OR], 2.316; 95% confidence interval [CI], 1.215~4.416; p=0.011). Non-adenocarcinoma histology (OR, 8.049; 95% CI, 4.072~15.911; p<0.001) and poorly differentiation (OR, 6.474; 95% CI, 2.998~13.979; p<0.001) were also independently associated with the presence of necrosis. However, p53 expression was not a significant factor for SUVmax.

Conclusion: p53 protein expression is independently associated with the presence of necrosis, but not SUVmax.

Key Words: Tumor Suppressor Protein p53; Necrosis; Positron-Emission Tomography; Carcinoma, Non-Small-Cell Lung

Introduction

The tumor suppressor p53 plays key roles in coordinating cellular responses to diverse stresses through transcriptional regulation of target gene expression[1]. Apoptosis, cell cycle arrest, DNA repair, and senescence are well-known cellular responses induced by p53 activation[2]. Recently, several lines of evidence have suggested that p53 acts as bioenergetic switch for cellular energy homeostasis. Activation of p53 up-regulates expression of TP53-induced glycolysis and apoptosis regulator, which lowers the fructose-2,6-bisphosphate level[3]. In addition, p53 suppresses expression of phosphoglycerate mutase and induces synthesis of cytochrome c oxidase subunit of complex IV of the electron transport chain in mitochondria[4,5]. Pharmacologic activation of AMP-activated protein kinase (AMPK) by metformin or aminoimidazole carboxamide ribonucleotide enhances oxidation of fatty acids, an alternative energy substrate for cancer cells, in a p53-dependent manner[6]. These p53-induced metabolic modulations may lead to a shift in glucose catabolism toward oxidative phosphorylation rather than glycolysis.

In contrast to its role in apoptosis induction p53 can exert a pro-survival effect, especially under conditions of metabolic stress. Two independent studies demonstrated that AMPK-dependent p53 activity is critical for

the maintenance of cellular viability under glucose-deprived conditions[7,8]. In addition, metformin selectively induced apoptotic cell death in metabolically-compromised areas of p53-deficient tumors[6].

p53 mutations that cause perturbation of p53 function are the most common mutations in human cancers, including non-small cell lung cancer (NSCLC)[1,2,9,10]. Based on the metabolic roles of p53, tumors with loss of p53 function are predicted to exhibit a glycolytic phenotype and have increased susceptibility to stress-induced cell death. These metabolic features of tumors could be reflected by increased maximal standardized uptake value (SUVmax) on ^{18}F-fluorodeoxyglucose positron emission tomography (^{18}F-FDG PET)/CT and by observation of cellular death in pathologic specimens[11]. p53 gene mutations cause accumulation of p53 protein in cancer cells, which is rarely seen for while wild-type p53[12]. Therefore, we investigated whether p53 protein expression, as a surrogate marker for loss of p53 function, is associated with metabolic features of stage I NSCLC, focusing on tumor necrosis and SUVmax on ^{18}F-FDG PET/CT.

Materials and Methods

1. Patients

We retrospectively reviewed medical records of patients who received surgical resection of NSCLC from March 2003 and August 2006 and obtained data on patient demographics, smoking status, preoperative staging work-up, and type of surgery. Tumor size, histological type, grade of differentiation, and visceral pleural invasion were determined from post-resection pathology reports. Pathologic stage was determined on the basis of all available data. Patients meeting the following criteria were included in this study: pathologic stage I NSCLC (excluding carcinoid, mucoepidermoid carcinoma, or adenoid cystic carcinoma) treated by lung resection surgery and mediastinal lymph node dissection or sampling; immunohistochemical staining of primary tumor for p53 expression; ^{18}F-FDG PET/CT imaging performed within 30 days of lung cancer surgery at the

Samsung Medical Center only; tumor diameter more than 1 cm due to spatial resolution of the PET scanner[13]; and no neoadjuvant therapy. Patients with no description of necrosis in the pathologic report were excluded. This study was approved by the Institutional Review Board of the Samsung Medical Center, which waived the requirement for informed consent of individual patients, given the retrospective nature of the study.

2. Immunohistochemistry and analysis

Immunohistochemical staining was performed using the avidin-biotinylated horseradish peroxidase complex method (DAKO LSAB kit). Briefly, 4-μm thick formalin-fixed paraffin-embedded lung tissue sections were prepared for immunohistochemistry. The tissue sections were deparaffinized in xylene and rehydrated through a series of alcohols. The sections were treated in 10 mmol/L citrate buffer (pH 6.0) for 10 minutes at 120°C in an autoclave for antigen retrieval, then incubated overnight at 4°C with mouse anti-p53 monoclonal antibody (1:20 dilution; BP 53.12; Invitrogen & Zymed Technologies, South San Francisco, CA, USA) followed by incubation with biotinylated anti-mouse IgG for 30 minutes. The tissue sections were treated with streptavidin-biotin complex peroxidase, followed by 3.3'diaminobenzidine tetrahydrochloride as the chromogen, and counterstained with hematoxylin. Nuclear staining of normal stromal cells was used as an internal control. The score of p53 immunoreactivity was expressed as the percentage of the total number of tumor cell nuclei showing p53 staining. Tumor p53-positivity was defined as a score $\geq 10\%$[14].

3. Integrated ^{18}F-FDG PET/CT acquisition and SUVmax analysis

All patients fasted for at least six hours before the positron emission tomography (PET)/computed tomography (CT) examination, although oral hydration with glucose-free water was allowed. After normal peripheral blood glucose level (≤ 150 mg/dL) was confirmed, patients received an intravenous injection of 370 MBq (10 mCi) ^{18}F-FDG and rested for approximately 45 minutes

before undergoing scanning. A PET/CT device (Discovery LS; GE Healthcare, Milwaukee, WI, USA) consisting of a PET scanner (Advance NXi; GE Medical Systems, Waukesha, WI, USA) and an 8-slice CT scanner (LightSpeed Plus; GE Medical Systems) was used for image acquisition. The ^{18}F-FDG PET data were evaluated using SUVmax because this is a semiquantitative and widely accepted index that characterizes the glycolytic activity of the tumor[11,15]. We used the region of interest analysis tools included with the scanner to calculate the SUVmax over the primary tumor after correction for the injected dose of ^{18}F-FDG and the patient's body weight.

4. Statistical analysis

We used the Students t-test for analysis of variables with normal distribution and the Mann-Whitney U test for variables without normal distribution. Categorical variables were analyzed by Pearson's chi-square test or Fisher's exact test. The linear-by-linear association method was used to test for trends across an ordinal categorical variable. For multivariate logistic regression analysis, independent variables were selected on the basis of clinical and biological relevance with necrosis and tested for associations between necrosis and independent variables using the enter method. Multiple linear regression with enter method was used for the analysis of associations between SUVmax and independent variables. Analyses were performed using an SPSS package, network version 17.0 (SPSS Inc., Chicago, IL, USA). All p-values reported are two-sided, and a p-value < 0.05 was considered significant.

Results

1. Patient characteristics

Between March 2003 and August 2006, 1,063 patients with NSCLC underwent surgical resection at the Samsung Medical Center. Of these, 508 patients had pathologic stage I NSCLC, and 241 met the eligibility criteria for this study. Baseline characteristics of the patients are summarized in Table 1. Most of tumors were adenocarcinoma or squamous cell carcinoma (223/241,

93%). p53 protein expression was detected in 112 (46%) tumors. Necrosis was observed in 104 (43%) tumors. The median SUVmax of primary tumors of NSCLC was 10.8. p53 expression was significantly associated with male gender, smoking, stage IB, presence of necrosis, and non-adenocarcinoma histology (Table 2). p53 ex-

Table 1. Baseline characteristics

Characteristic	No. (%)
Age, yr	
Median	63
Range	32~85
Gender	
Female	54 (22)
Male	187 (78)
Smoker*	
Never	72 (31)
Ever	164 (69)
Histology	
Adenocarcinoma	126 (52)
Squamous cell carcinoma	97 (40)
Large neuroendocrine carcinoma	7 (3)
Large cell carcinoma	5 (2)
Pleomorphic carcinoma	4 (2)
Others[†]	2 (1)
Stage	
IA	82 (34)
IB	159 (66)
Tumor size, cm	
≤2	62 (26)
>2~3	64 (27)
≤5	83 (34)
>5	32 (13)
Differentiation	
Well	55 (23)
Moderately	125 (52)
Poorly	61 (25)
Necrosis	
Absence	139 (57)
Presence	104 (43)
p53 expression	
Negative	129 (54)
Positive	112 (46)
SUVmax	
Median	10.8
Range	0.5~43.4

*Smoking history available for 236 of 241 patients, [†]Includes adenosquamous carcinoma and unspecified non-small cell lung cancer.
SUVmax: maximal standardized uptake value.

pression increased significantly as the histological grade of differentiation progressed (p=0.008). SUVmax of p53-positive tumors was significantly higher than that of p53-negative tumors (12.6 vs. 8.1; p＜0.001).

2. p53 protein expression is independently associated with necrosis

The presence of necrosis was significantly associated with male gender, smoking, stage IB, non-adencarcinoma histology, progression of histological grade of differentiation, and p53 expression (Table 3). Multivariate logistic regression analysis adjusted for stage, histol-

Table 2. Relationship between p53 expression and clinical characteristics in patients with stage I non-small cell lung cancer

Characteristic	p53 (−) (n=129)	p53 (+) (n=112)	p-value
Age, yr			0.155
Median	61	63	
Range	37~78	32~85	
Gender			0.028
Female	36 (28)	18 (16)	
Male	93 (72)	94 (84)	
Smoker*			0.007
Never	48 (38)	24 (22)	
Ever	78 (62)	86 (78)	
Stage			0.006
IA	54 (42)	28 (25)	
IB	75 (58)	84 (75)	
Histology			＜0.001
ADC	84 (65)	42 (37)	
Non-ADC	45 (35)	70 (63)	
Differentiation			0.008
Well	39 (30)	16 (14)	
Moderately	62 (48)	63 (56)	
Poorly	28 (22)	33 (30)	
Necrosis			＜0.001
Absence	91 (70)	46 (41)	
Presence	38 (30)	66 (59)	
SUVmax			＜0.001
Median	8.1	12.6	
IQR	4.2~13.9	7.2~16.8	

Data are presented as number (%) unless otherwise indicated. *Smoking history available for 236 of 241 patients. p53 (−): p53-negative; p53 (+): p53-positive; ADC: adenocarcinoma; SUVmax: maximal standardized uptake value; IQR: interquartile range.

Table 3. Relationship between necrosis and clinical characteristics in patients with stage I non-small cell lung cancer

Characteristic	Necrosis (−) (n=139)	Necrosis (+) (n=104)	p-value
Age, yr			0.128
Median	61	63	
Range	53~69	56~69	
Gender			＜0.001
Female	45 (33)	9 (9)	
Male	92 (67)	95 (91)	
Smoker*			＜0.001
Never	58 (43)	14 (14)	
Ever	77 (57)	87 (86)	
Stage			＜0.001
IA	61 (45)	21 (20)	
IB	76 (55)	83 (80)	
Histology			＜0.001
ADC	101 (74)	25 (24)	
Non-ADC	36 (26)	79 (76)	
Differentiation			＜0.001
Well	48 (35)	7 (7)	
Moderately	72 (53)	53 (51)	
Poorly	17 (12)	44 (42)	
p53			＜0.001
Absence	91 (70)	46 (41)	
Presence	38 (30)	66 (59)	

Data are presented as number (%) unless otherwise indicated. *Smoking history available for 236 of 241 patients. Necrosis (−): absence of necrosis; Necrosis (+): presence of necrosis; ADC: adenocarcinoma.

Table 4. Multivariate logistic regression for defining independent variables associated with necrosis in patients with stage I non-small cell lung cancer

Variable	Odds ratio	95% CI	p-value
Stage			0.071
IA	1.000		
IB	1.955	0.945~4.047	
Histology			＜0.001
ADC	1.000		
Non-ADC	8.049	4.072~15.911	
Differentiation			＜0.001
Well and Moderately	1.000		
Poorly	6.474	2.998~13.979	
p53 expression			0.011
Negative	1.000		
Positive	2.316	1.215~4.416	

CI: confidence interval; ADC: adenocarcinoma.

**Figure 1.** Surgical specimens of non-small cell lung cancer without necrosis (A) or with necrosis (B, arrow) (H&E stain, ×100). Immunostainings for p53 (C~F). No p53 expression was observed in the nuclei of non-small cell lung cancer without necrosis (C, p53 immunostaining, ×100; E, p53 immunostaining, ×400). p53 is strongly expressed in the nuclei of non-small cell lung cancer with necrosis (D, p53 immunostaining, ×100; F, p53 immunostaining, ×400).

ogy (adenocarcinoma vs non-adenocarcinoma), grade of differentiation (well and moderately vs. poorly), and p53 expression revealed that p53 expression was independently associated with the presence of necrosis (odds ratio [OR], 2.316; 95% confidence interval [CI], 1.215~4.416; p=0.011) (Table 4, Figure 1). Non-adenocarcinoma histology (OR, 8.049; 95% CI, 4.072~15.911; p<0.001) and poorly differentiation (OR, 6.474;

95% CI, 2.998~13.979; p<0.001) were also independently associated with the presence of necrosis (Table 4).

Significantly higher SUVmaxs were observed in male gender (12.1 vs. 5.9; p<0.001), smoker (12.5 vs. 5.9; p<0.001), stage IB (12.5 vs. 6.8; p<0.001), non-adenocarinoma (14.5 vs. 6.0; p<0.001), and poorly differentiation (13.7 vs. 8.8; p<0.001) compared the counterparts. After adjustment for stage, histology, grade of differentiation, and p53 expression for multiple linear regression analysis, stage IB (coefficient, 2.805; standard error [SE], 0.798; p=0.001), poorly differentiation (coefficient, 2.006; SE, 0.835; p=0.017), non-adenocarcinoma (coefficient,7.219; SE, 0.776; p<0.001) were found to be independent variables for SUVmax. However, p53 expression was not a significant variable for SUVmax (p=0.694).

Discussion

Metabolic adaptations are critically important for cancer cells to sustain viability under conditions of bioenergetic stress. Recent studies demonstrated that p53 activity is critical for cancer cells to overcome metabolic stress[7,8]. In contrast to genotoxic stress, which induces cellular apoptosis via p53 activation, metabolic stress activates a pro-survival function of p53[7,8]. In the present study, we demonstrated that p53 expression was a significant and independent factor associated with tumor necrosis in patient with stage I NSCLC. Of note, all cases in this study had no history of chemotherapy or radiotherapy before surgical resection; therefore the presence of necrosis reflects naturally occurring cell death caused by failure to overcome various metabolic stresses during the early course of NSCLC progression. The association between necrosis and p53 expression thus provides additional indirect support for a pro-survival function of the tumor suppressor p53 in cancer.

Enhanced glucose uptake is a fundamental characteristic of cancer cell metabolism that could be assessed by measuring SUVmax of primary tumor via ^{18}F-FDG PET[11,15]. Glucose transporter, hexokinase, phosphofructokinase, hypoxia-inducible factor-1alpha (HIF-1α),

c-Myc, ras, Akt, and p53 are important molecules that contribute to glycolytic activity of cancer cells[11]. In clinical settings, several studies have reported that expression of glucose transporter 1, HIF-1α, p53, and Ki-67 are significantly correlated with high SUVmax in lung cancer[16-19]. In agreement with previous reports[16,20], this study found a significantly higher SUVmax in p53-positive NSCLC than in p53-negative NSCLC upon univariate analysis. However, p53 expression was not an independent factor for SUVmax in this study. Actually, non-adenocarcinoma histology, poorly differentiation, and stage IB were found to be independent factors for SUVmax. SUVmax on ^{18}F-FDG PET is a semiquantitative index which might be affected by fasting duration, plasma glucose level, region of interest parameters, and cellular density of tumors[21]. To investigate the association between molecular markers and SUVmax, subgrouping according to histology, grade of differentiation, and stage might be necessary in the future study.

p53 expression assessed by immunohistochemistry were used as a surrogate marker of p53 mutations in this study. Indeed, p53 protein expression typically represents missense mutations and not all mutations of the p53 gene[22]. However, most of the mutations identified in lung cancers are missense mutations[22], and several studies have demonstrated clinical implications of p53 status assessed by immunohistochemistry as a surrogate marker of p53 mutations in lung cancer[23-25]. Furthermore, immunohistochemistry is a simple method to perform using clinical samples. Because tumor p53-positivity was defined as a score ≥10% in a previous research from our institution using NSCLC tissues[14], we applied the same criteria in this study. However, further study to validate the criteria is needed. To reduce bias in the interpretation of p53 expression, immunohistochemical evaluation incorporated both stain intensity and percentage such as HSCORE may be helpful in the future study[26].

In summary, p53 protein expression is independently associated with the presence of necrosis, but not SUVmax in patients with stage I NSCLC.

Acknowledgements

References

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
3. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-20.
4. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005;65:177-85.
5. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science 2006;312:1650-3.
6. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52.
7. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005;18:283-93.
8. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 2008;283:3979-87.
9. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
10. Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J, et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 2000;60:3155-9.
11. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 2008;27:545-54.
12. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol 1994;172:1-4.
13. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004;45:19-27.
14. Kwon YM, Park JH, Kim H, Shim YM, Kim J, Han J, et al. Different susceptibility of increased DNMT1 expression by exposure to tobacco smoke according to histology in primary non-small cell lung cancer. J Cancer Res Clin Oncol 2007;133:219-26.
15. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12.
16. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, et al. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:43-8.
17. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:1610-6.
18. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-8.
19. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11-7.
20. Zhang ZJ, Chen JH, Meng L, Du JJ, Zhang L, Liu Y, et al. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer. Chin Med J (Engl) 2007;120:125-31.
21. Bacharach SL, Sundaram SK. 18F-FDG in cardiology and oncology: the bitter with the sweet. J Nucl Med 2002;43:1542-4.
22. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003;21:229-39.

23. D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117:736-43.

24. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.

25. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18: 705-19.

26. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986;46(8 Suppl): 4244s-8s.